Drug intelligence / Profile preview

P4M01

Development stage: Unknown
Lead developer: P4 Microbiome
Modality: Peptides
Administration: Topical, Oral

Overview

P4M01 is an antimicrobial peptide therapeutic developed by D&D Pharmatech through its subsidiary, P4 Microbiome. Originally in-licensed from the U.S. Department of Defense (U.S. Army), P4M01 is designed to treat inflammatory and infectious diseases by modulating the microbiome. It has successfully completed a Phase 2a clinical trial for periodontal disease, demonstrating both safety and efficacy. The drug is also being investigated in preclinical studies for its potential application in treating gastrointestinal conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

Beyond the preview

Go deeper on P4M01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P4M01.

Explore the full profile